Setipiprant

Role of viral respiratory infections in asthma and asthma exacerbations, airflow obstruction associated with increased smooth muscle extracellular matrix, asthma therapy and airway remodeling, biologics and airway remodeling in severe asthma, phenotype- and patient-specific modeling in asthma, prostaglandin D2 receptor 2 pathway in asthma, prostaglandin D2-induced bronchoconstriction, prostaglandin D2 pathway upregulation in relation to asthma severity, CRTH2 antagonism reducing allergen-induced airway responses, DP2 antagonism reducing airway smooth muscle mass, fevipiprant efficacy in reducing exacerbations in severe asthma, DP2 antagonist GB001 for asthma, PGD2/DP2 receptor activation promoting severe viral bronchiolitis, increased expression of inducible nitric oxide synthase and cyclo-oxygenase-2 in asthmatic airway epithelium, effects of topical corticosteroids on eicosanoid release by airway epithelial cells, glucocorticoid-regulated inflammatory cyclooxygenase, aeroallergen-induced IL-33 predisposing to respiratory virus-induced asthma, targeting P2Y13 receptor suppressing IL-33 and HMGB1 release, chronic IL-33 expression predisposing to virus-induced asthma exacerbations, viral infections and atopy in asthma pathogenesis, DP1 prostanoid receptor activation increasing severity of acute lower respiratory viral infection, virus-induced inflammasome activation suppressed by prostaglandin D2/DP1 signaling, airway hyperresponsiveness and inflammation in mild asthma, airway remodeling-associated mediators in moderate to severe asthma, transforming growth factor β1 function in airway remodeling, anti-IL-5 treatment reducing ECM protein deposition, effects of influenza on alveolar macrophage viability, macrophage polarization and allergic asthma, CRTH2 antagonism effect on rhinovirus infection response, expression of c-erbB receptors and ligands in asthmatic bronchial epithelium, epidermal growth factor receptor involvement in epithelial repair, epithelial damage and response in asthma, cluster analysis of nasal cytokines during rhinovirus infection, proteins associated with airway fibrosis in allergic asthma and rhinitis, amphiregulin, histamine inducing airway remodeling through EGF receptor ligand release, expression and function of the epidermal growth factor receptor, oxidized IL-33 signaling via RAGE/EGFR driving COPD phenotype, myeloid cell subsets classification, TNF-α sensitizing lung fibroblasts to Fas-induced apoptosis, antagonistic effects of TNF-α on TGF-β signaling, increased cell surface Fas expression sensitizing lung fibroblasts to apoptosis, IL-33-induced neutrophilic inflammation and NETosis in rhinovirus-triggered asthma, DP1 activation reversing age-related hypertension, prostaglandin D2-D prostanoid 1 signaling reducing intestinal permeability, activated prostaglandin D2 receptors enhancing neutrophil recruitment, pharmacologic profile of OC000459, hematopoietic prostaglandin D synthase inhibitor PK007, effect of fluticasone propionate on virus-induced airways inflammation, anti-TIM3 antibody promoting antitumor immunity, PAG1 limiting allergen-induced type 2 inflammation, HMGB1 amplifying ILC2-induced type-2 inflammation, PGD2/DP2 receptor activation promoting severe viral bronchiolitis, maternal diet modulating infant microbiome and immunity to respiratory infection, plasmacytoid dendritic cells protecting from viral bronchiolitis through T reg expansion.